Privigen 20g
Biological
CSL Behring
Total Payments
$106,080
Transactions
5
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $106,080 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $106,080 | 5 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Open Label Study of SCIg in myasthenia gravis (MG) | CSL Behring | $87,040 | 0 |
| A study of subcutaneous immunoglobulin as chronic treatment for patients with chronic inflammatory demyelinating polyneuropathy | CSL Behring | $13,600 | 0 |
| In vivo research in animal models of organ transplantation | CSL Behring | $5,440 | 0 |
Top Doctors Receiving Payments for Privigen 20g
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Tampa, FL | $106,080 | 5 |
Ad
Manufacturing Companies
- CSL Behring $106,080
Product Information
- Type Biological
- Total Payments $106,080
- Total Doctors 0
- Transactions 5
About Privigen 20g
Privigen 20g is a biological associated with $106,080 in payments to 0 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2017 to 2017. In 2017, $106,080 was paid across 5 transactions to 0 doctors.
The most common payment nature for Privigen 20g is "Unspecified" ($106,080, 100.0% of total).
Privigen 20g is associated with 3 research studies, including "Open Label Study of SCIg in myasthenia gravis (MG)" ($87,040).